Literature DB >> 28829958

A randomized controlled study of brief family-based intervention in obsessive compulsive disorder.

Upasana Baruah1, R Dhanasekara Pandian2, Janardhanan C Narayanaswamy3, Suresh Bada Math3, Thennarasu Kandavel4, Y C Janardhan Reddy3.   

Abstract

BACKGROUND: Cognitive behaviour therapy (CBT) for Obsessive Compulsive Disorder (OCD) is therapist-intensive and prolonged making it less accessible to patients, particularly in resource-constrained situations. We examined the efficacy of a brief psychotherapeutic intervention as an adjunct to serotonin reuptake inhibitors (SRIs) in OCD.
METHOD: We randomized 64 adult OCD patients stabilized on SRIs to either the 6-session brief family-based intervention (BFBI; n = 30) that included psychoeducation, exposure and response prevention and family intervention or to a control arm of relaxation exercises (RE). Assessments were conducted at baseline and at 1- and 3- months post-intervention. Primary outcome measure was response to treatment defined as ≥ 35% reduction in the Yale-Brown Obsessive Compulsive Scale total score relative to baseline score plus a Clinical Global Impression- Improvement rating of very much improved or much improved. Family accommodation and expressed emotions were also assessed.
RESULTS: At 3- month follow-up, the BFBI group responded better than the RE group (53% vs. 12%, p < 0.001). Illness severity, family accommodation and expressed emotion declined significantly over time in the BFBI group compared to the RE group. The BFBI (OR = 13.17, p < 0.001) and baseline illness severity (OR = 0.746, p < 0.011) predicted treatment response. LIMITATIONS: Sample size was small and follow-up duration was short. Control group had less time with the therapist although number of sessions was identical in both the groups.
CONCLUSION: Briefer intervention is effective in treating OCD. Briefer and inclusive format of intervention has important implications for clinical practice in resource-constrained circumstances.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brief intervention; Family-based; Obsessive compulsive disorder; Randomized controlled trial

Mesh:

Substances:

Year:  2017        PMID: 28829958     DOI: 10.1016/j.jad.2017.08.014

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  6 in total

1.  Unravelling 'low-resource settings': a systematic scoping review with qualitative content analysis.

Authors:  Chanel van Zyl; Marelise Badenhorst; Susan Hanekom; Martin Heine
Journal:  BMJ Glob Health       Date:  2021-06

Review 2.  Expressed Emotion Research in India: A Narrative Review.

Authors:  Anvar Sadath; Ram Kumar; Magnus Karlsson
Journal:  Indian J Psychol Med       Date:  2019 Jan-Feb

3.  Clinical Practice Guidelines for Cognitive-Behavioral Therapies in Anxiety Disorders and Obsessive-Compulsive and Related Disorders.

Authors:  Y C Janardhan Reddy; Paulomi M Sudhir; M Manjula; Shyam Sundar Arumugham; Janardhanan C Narayanaswamy
Journal:  Indian J Psychiatry       Date:  2020-01-17       Impact factor: 1.759

4.  Effect of Family and Patient Centered Empowerment Program on Depression, Anxiety and Stress in Patients with Obsessive-Compulsive Disorder and Their Caregivers' Burden.

Authors:  Tahereh Heidari; Seyed-Mohammad Mousavi; Seyed-Nouraddin Mousavinasab; Hamideh AzimiLolaty
Journal:  Iran J Nurs Midwifery Res       Date:  2020-11-07

5.  The Chinese version of the family accommodation scale for obsessive-compulsive disorder self-rated: reliability, validity, factor structure, and mediating effect.

Authors:  Zhenhua Liao; Lijun Ding; Ciping You; Ying Chen; Wenchang Zhang
Journal:  Front Psychiatry       Date:  2022-08-11       Impact factor: 5.435

6.  Treatment Adherence as Predictor of Outcome in Concentrated Exposure Treatment for Obsessive-Compulsive Disorder.

Authors:  Kristian Tjelle; Håvard Berg Opstad; Stian Solem; Gunvor Launes; Bjarne Hansen; Gerd Kvale; Kristen Hagen
Journal:  Front Psychiatry       Date:  2021-06-24       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.